

FORM 27
SECURITIES ACT (ALBERTA)

Material Change Report under Section 118(1)
of the *Securities Act* (Alberta)

1. Reporting Issuer:

Biolix Corporation/Corporation Biolix

Head Office : 1175, de Lavigerie, suite 50, Sainte-Foy, Québec G1V 4P1

2. Material Change occurred on:

November 2, 2001

3. News Release:

November 9, 2001

4. Summary of Material Change:

On November 2, 2001 the Corporation appointed Mr. Paul Boudreault as its new President and Chief Executive Officer, thus replacing Mr. Jean-Louis Sasseville, who will remain with the Corporation as the President of the Board de Directors.

5. Full Description of Material Change:

See attached Schedule "A" – Press release detailing the material change issued on November 9, 2001.

6. Reliance on Section 118(2) of the *Securities Act* (Alberta)

Not applicable

7. Omitted Information:

Not applicable

8. Senior Officer:

Mr. Georges Lachapelle

1175, de Lavigerie, suite 50,
Sainte-Foy, Québec
G1V 4P1

Telephone (418) 266-5584

Fax (418) 266-5587

9. Statement of Senior Officer:

The foregoing accurately discloses the material change referred to herein.

DATED in Quebec, Quebec, on the 8th day of November 2001

BIOLIX CORPORATION

(s) Georges Lachapelle
Per : _____
Georges Lachapelle
Corporate secretary

IT IS AN OFFENCE UNDER THE SECURITIES ACT AND THE SECURITIES REGULATION FOR A PERSON OR COMPANY TO MAKE A STATEMENT IN A DOCUMENT REQUIRED TO BE FILED OR FURNISHED UNDER THE ACT OR THE REGULATION THAT, AT THE TIME AND IN THE LIGHT OF THE CIRCUMSTANCES UNDER WHICH IT IS MADE, IS A MISREPRESENTATION.

SCHEDULE “A”



Press release

For immediate release

PAUL BOUDREAUPT APPOINTED PRESIDENT AND CEO OF BIOLIX

*Claude Vezeau and Paul Lafleur
join company's Board of Directors*

Quebec (Quebec), November 9, 2001 – Mr. Jean-Louis Sasseville, Chairman of the Board of BIOLIX Corporation “BIOLIX” (CDNX: BXC) of Quebec, is pleased to announce the appointment of Mr. Paul Boudreau to the position of President and Chief Executive Officer of the company. Until now, this position was held by Mr. Sasseville. Since November 2000, Mr. Boudreau has been the Executive Vice-President of BIOLIX.

“BIOLIX is entering the commercialization stage of its growth. Mr. Boudreau is the ideal person to take charge of the company as it enters this new phase and ensure that it fulfils its commercial and operational potential,” stated Mr. Sasseville.

Before joining BIOLIX, Mr. Boudreau successfully led numerous environmental programs, particularly in the water treatment sector. He has also participated in many projects abroad, especially in Europe.

“BIOLIX is already well-positioned internationally,” explained Mr. Boudreau. Recently, we signed a partnership agreement with the company ONDEO (formerly Lyonnaise des eaux), a world leader in water treatment. As a result of this agreement, our innovative procedure for treating heavy metals,

“Metix”, is starting to be commercialized in France. Now that we have gained momentum, we are confident that we can quickly generate income and create value for our shareholders.”

In other news, BIOLIX also recently welcomed Ms. Suzanne Delisle to its team as Director, Finance and Administration. Ms. Delisle has a great deal of experience in administrative management, particularly in the bio-pharmaceutical sector. Notably, she previously held the position of Vice-President, Finance and Administration, at BioChem Vaccines, a subsidiary of BioChem Pharma.

Jean-Louis Sasseville, in addition to staying on as Chairman of the Board, will also head the new scientific committee at BIOLIX.

New key players on Board of Directors

Also, Mr. Sasseville is proud to announce the appointment of Dr. Claude Vezeau and Mr. Paul Lafleur to BIOLIX’s Board of Directors.

Dr. Vezeau is the Vice-President, Investments at BioCapital, an important investor in the biotechnology sector. Previously, he worked for several years in the pharmaceutical sector, and held, notably, the position of President of BioChem Vaccines.

“Dr. Vezeau’s expertise is a valuable asset for BIOLIX. He possesses a thorough knowledge of the bio-pharmaceutical field from the financial, operational and scientific standpoints,” underlined Mr. Sasseville.

Mr. Paul Lafleur, holds the position of President and CEO of BPR Groupe-Conseil, an important engineering firm based in Quebec which conducts business internationally. Many municipalities, forestry and agricultural companies use the services offered by BPR Groupe-Conseil.

“BPR’s joint venture experience with ONDEO, its know-how in various spheres of activity, many of which are also target markets for BIOLIX, will be of tremendous value to our company. Added to this knowledge is Mr. Lafleur’s leadership qualities and personal experience which will no doubt prove highly useful to BIOLIX,” said Mr. Sasseville.

Furthermore, Mr. Jean-Paul Cloutier has also announced his resignation from BIOLIX’s Board of Directors for personal reasons.

The appointments of Mr. Boudreault, Mr. Lafleur and Mr. Vezeau were ratified a few days ago during the last meeting of Biolix’s Board of Directors.

Established in 1998 and listed on the Canadian Venture Exchange, BIOLIX is a company that designs and brings to market new technologies related to the decontamination and valorization of sludges left over from municipal, industrial and agricultural waste water treatment.

- 30 -

Source:

Biolix Corporation
www.biolix.com

For more information: **Georges Lachapelle**
Corporate Secretary
BIOLIX
Phone: (418) 266-5584

Julie Fortier
Communications Consultant
Hill&Knowlton/Ducharme Perron
Phone: (514) 395-0375, ext. 238

The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

